Zimmer Biomet Q4 2023 Earnings Report
Key Takeaways
Zimmer Biomet reported a strong finish to 2023 with Q4 net sales increasing by 6.3% to $1.940 billion and diluted earnings per share at $2.01. The company's full-year net sales reached $7.394 billion, a 6.5% increase, with diluted earnings per share at $4.88. The company is providing full-year 2024 financial guidance.
Fourth quarter net sales increased 6.3% to $1.940 billion, or 6.1% on a constant currency basis.
Fourth quarter diluted earnings per share (EPS) were $2.01; adjusted diluted EPS were $2.20.
Full-year net sales increased 6.5% to $7.394 billion, or 7.5% on a constant currency basis.
Full-year diluted earnings per share (EPS) were $4.88; adjusted diluted EPS were $7.55.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Forward Guidance
The Company is providing the following full-year 2024 financial guidance: 2024 Reported Revenue Change 4.5% - 5.5%, Foreign Currency Exchange Impact (0.5)%, 2024 Constant Currency Revenue Change 5.0% - 6.0%, Adjusted Diluted EPS $8.00 - $8.15
Revenue & Expenses
Visualization of income flow from segment revenue to net income